Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

ZC88, a novel 4-amino piperidine analog, inhibits the growth of neuroblastoma cells through blocking hERG potassium channel.

Wei X, Sun H, Yan H, Zhang C, Zhang S, Liu X, Hua N, Ma X, Zheng J.

Cancer Biol Ther. 2013 May;14(5):450-7. doi: 10.4161/cbt.24423.

2.

Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in vitro and in vivo.

Zhao J, Wei XL, Jia YS, Zheng JQ.

Eur J Pharmacol. 2008 Jan 28;579(1-3):50-7. Epub 2007 Oct 13.

PMID:
17976575
3.

Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells.

Glassmeier G, Hempel K, Wulfsen I, Bauer CK, Schumacher U, Schwarz JR.

Pflugers Arch. 2012 Feb;463(2):365-76. doi: 10.1007/s00424-011-1045-z. Epub 2011 Nov 11.

4.

The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.

Tang Q, Li ZQ, Li W, Guo J, Sun HY, Zhang XH, Lau CP, Tse HF, Zhang S, Li GR.

Br J Pharmacol. 2008 Oct;155(3):365-73. doi: 10.1038/bjp.2008.261. Epub 2008 Jun 23.

5.

[Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].

Shang BY, Shang Y, Zhen YS, Chen SZ.

Yao Xue Xue Bao. 2011 Nov;46(11):1321-5. Chinese.

PMID:
22260022
6.

Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).

Gerlach AC, Stoehr SJ, Castle NA.

Mol Pharmacol. 2010 Jan;77(1):58-68. doi: 10.1124/mol.109.059543. Epub 2009 Oct 5.

7.

ZC88, a novel N-type calcium channel blocker from 4-amino-piperidine derivatives state-dependent inhibits Cav2.2 calcium channels.

Zhang S, Yang L, Zhang K, Liu X, Dai W, Zhang C, Yong Z, Li J, Zheng J.

Brain Res. 2015 Apr 24;1605:12-21. doi: 10.1016/j.brainres.2015.01.054. Epub 2015 Feb 12.

PMID:
25681549
8.

The antipsychotic drug chlorpromazine inhibits HERG potassium channels.

Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, Karle CA.

Br J Pharmacol. 2003 Jun;139(3):567-74.

9.

Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate.

Dong Q, Fu XX, Du LL, Zhao N, Xia CK, Yu KW, Cheng LX, Du YM.

Biol Pharm Bull. 2013;36(2):268-75. Epub 2012 Nov 30.

10.

Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration.

Hong HK, Lee BH, Park MH, Lee SH, Chu D, Kim WJ, Choe H, Hee Choi B, Jo SH.

Eur J Pharmacol. 2013 Feb 28;702(1-3):165-73. doi: 10.1016/j.ejphar.2013.01.039. Epub 2013 Feb 6.

PMID:
23395964
11.

Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.

Zhang P, Xing J, Luo A, Feng J, Liu Z, Gao C, Ma J.

J Pharm Pharmacol. 2013 Sep;65(9):1321-8. doi: 10.1111/jphp.12095. Epub 2013 Jul 10.

PMID:
23927470
12.

Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.

Xing J, Ma J, Zhang P, Fan X.

Eur J Pharmacol. 2010 Mar 25;630(1-3):1-9. doi: 10.1016/j.ejphar.2009.11.009. Epub 2009 Nov 10.

PMID:
19903464
13.

Novel roles for hERG K(+) channels in cell proliferation and apoptosis.

Jehle J, Schweizer PA, Katus HA, Thomas D.

Cell Death Dis. 2011 Aug 18;2:e193. doi: 10.1038/cddis.2011.77. Review.

14.

Long-term channel block is required to inhibit cellular transformation by human ether-à-go-go-related gene (hERG1) potassium channels.

Pier DM, Shehatou GS, Giblett S, Pullar CE, Trezise DJ, Pritchard CA, Challiss RA, Mitcheson JS.

Mol Pharmacol. 2014 Aug;86(2):211-21. doi: 10.1124/mol.113.091439. Epub 2014 May 15.

15.

Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.

Su Z, Chen J, Martin RL, McDermott JS, Cox BF, Gopalakrishnan M, Gintant GA.

Biochem Pharmacol. 2006 Jan 12;71(3):278-86. Epub 2005 Dec 1.

PMID:
16325148
16.

Comparative effects of loratadine and terfenadine on cardiac K+ channels.

Ducic I, Ko CM, Shuba Y, Morad M.

J Cardiovasc Pharmacol. 1997 Jul;30(1):42-54.

PMID:
9268220
17.

Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.

Kushida S, Ogura T, Komuro I, Nakaya H.

Eur J Pharmacol. 2002 Dec 13;457(1):19-27.

PMID:
12460639
18.

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

Karczewski J, Wang J, Kane SA, Kiss L, Koblan KS, Culberson JC, Spencer RH.

Biochem Pharmacol. 2009 May 15;77(10):1602-11. doi: 10.1016/j.bcp.2009.02.011. Epub 2009 Feb 27.

PMID:
19426697
19.

Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.

Durdagi S, Duff HJ, Noskov SY.

J Chem Inf Model. 2011 Feb 28;51(2):463-74. doi: 10.1021/ci100409y. Epub 2011 Jan 11.

PMID:
21241063
20.

[Erythromycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].

Chen SZ, Zhang SH, Gong JH, Zhen YS.

Zhonghua Yi Xue Za Zhi. 2006 Dec 19;86(47):3353-7. Chinese.

PMID:
17313833

Supplemental Content

Support Center